Kamada Company Profile (NASDAQ:KMDA)

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: KMDA
CUSIP:

Key Metrics:

Previous Close: $5.24
50 Day Moving Average: $4.55
200 Day Moving Average: $4.03
52-Week Range: $3.24 - $5.34
Trailing P/E Ratio: N/A
Foreward P/E Ratio: 87.33
P/E Growth: -4.34
Market Cap: $190.83M
Outstanding Shares: 36,418,000
Beta: 1.16

Profitability:

Net Margins: -9.92%
Return on Equity: -10.59%
Return on Assets: -7.24%

Debt:

Debt-to-Equity Ratio: 0.02%
Current Ratio: 3.55%
Quick Ratio: 2.24%

Additional Links:

Companies Related to Kamada:

Consensus Ratings for Kamada (NASDAQ:KMDA) (?)

Ratings Breakdown:	2 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$8.50 (62.21% upside)

Analysts' Ratings History for Kamada (NASDAQ:KMDA)

Show:

Date	Firm	Action	Rating	Price Target
9/3/2016	HC Wainwright	Reiterated Rating	Buy	$10.00
8/31/2016	Jefferies Group	Reiterated Rating	Buy	$7.00
1/7/2015	Royal Bank Of Canada	Set Price Target	Buy	$8.00

(Data available from 9/26/2014 forward)

Earnings History for Kamada (NASDAQ:KMDA)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/2/2016	Q216	($0.04)	($0.04)	$18.50 million	$19.10 million	View	N/A
2/2/2016	Q415	($0.09)	$0.03	$27.10 million	$25.90 million	View	N/A
11/10/2015	Q315	($0.04)	($0.13)	$18.67 million	$16.10 million	View	Listen
7/30/2015	Q215	($0.03)	($0.06)	$21.82 million	$19.20 million	View	Listen
5/12/2015	Q115	($0.05)	($0.15)	$16.12 million	$9.00 million	View	Listen
2/11/2015	Q4	$0.01	$0.05			View	N/A
11/13/2014	Q314	($0.04)	($0.09)	$19.00 million	$17.20 million	View	N/A
8/14/2014	Q214	($0.02)	($0.23)	$17.17 million	$15.80 million	View	N/A
5/8/2014	Q114	($0.03)	($0.09)	$15.97 million	$13.20 million	View	N/A
2/5/2014	Q413	$0.05	$0.04	$25.22 million	$24.40 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Kamada (NASDAQ:KMDA)

Current Year EPS Consensus Estimate: $-0.19 EPS
Next Year EPS Consensus Estimate: $0.06 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	($0.11)	($0.11)	($0.11)
Q2 2016	1	($0.04)	($0.04)	($0.04)
Q3 2016	1	($0.01)	($0.01)	($0.01)
Q4 2016	1	$0.00	$0.00	$0.00

(Data provided by Zacks Investment Research)

Dividend History for Kamada (NASDAQ:KMDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Kamada (NASDAQ:KMDA)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Kamada (NASDAQ:KMDA)

Date	Headline
	LifeSci Capital Initiates Coverage of Kamada (NASDAQ:KMDA) finance.yahoo.com - September 12 at 5:38 PM
	Kamada to Present a Corporate Overview at the Rodman & Renshaw 18th Annual Investment Conference (NASDAQ:KMDA) finance.yahoo.com - September 9 at 10:35 AM
	4 Biotechs Set to Provide a Shot in the Arm (NASDAQ:KMDA) realmoney.thestreet.com - September 9 at 10:35 AM
	H.C. Wainwright Talks Kamada's Recent Phase 2 Results (NASDAQ:KMDA) www.benzinga.com - September 1 at 5:42 PM
	Marketing application filed in U.S. for Kamada's post-exposure rabies therapy; launch planned in 2017 (NASDAQ:KMDA) seekingalpha.com - September 1 at 8:54 AM
	Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment (NASDAQ:KMDA) www.publicnow.com - September 1 at 8:54 AM
	Kamada succeeds in phase 2 inhaled drug trial (NASDAQ:KMDA) www.globes.co.il - August 31 at 10:40 AM
	Kamada (KMDA): Phase II Trial Adds Support For Inhaled AAT Therapy - Jefferies (NASDAQ:KMDA) www.streetinsider.com - August 31 at 10:40 AM
	Kamada's Phase 2 Trial Of Alpha-1 Antitrypsin Therapy Meets Primary Endpoint (NASDAQ:KMDA) www.nasdaq.com - August 30 at 9:06 AM
	Mid-stage study of Kamada's inhaled AAT therapy in AATD successful; shares up 7% premarket (NASDAQ:KMDA) seekingalpha.com - August 30 at 9:06 AM
	Kamada's (KMDA) Inhaled Alpha-1 Antitrypsin Phase 2 Met Primary Endpoint (NASDAQ:KMDA) www.streetinsider.com - August 30 at 9:06 AM
	Kamada Meets Primary Endpoint of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of Alpha-1 Antitrypsin Deficiency (NASDAQ:KMDA) www.publicnow.com - August 30 at 9:06 AM
	Kamada's Phase 2 Trial On Inhaled Alpha-1 Antitrypsin Meets Primary Endpoint (NASDAQ:KMDA) feeds.benzinga.com - August 30 at 8:38 AM
	Biotest : Kamada recalls imported drug (NASDAQ:KMDA) www.4-traders.com - August 17 at 6:02 PM
	Kamada recalls imported drug (NASDAQ:KMDA) www.globes.co.il - August 16 at 9:06 AM
	Our Take On Kamada Ltd (KMDA)’s Upcoming Catalysts (NASDAQ:KMDA) feedproxy.google.com - August 9 at 1:02 PM
	Kamada Ltd. :KMDA-IL: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (NASDAQ:KMDA) www.capitalcube.com - August 9 at 8:53 AM
	Kamada Ltd. :KMDA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:KMDA) www.capitalcube.com - August 5 at 6:00 PM
	Kamada Reports Financial Results for the Second Quarter and First Six Months of 2016 (NASDAQ:KMDA) www.publicnow.com - August 3 at 9:04 AM
	Kamada reports 2Q loss (NASDAQ:KMDA) sg.finance.yahoo.com - August 2 at 10:42 AM
	ETF’s with exposure to Kamada Ltd. : July 26, 2016 (NASDAQ:KMDA) www.capitalcube.com - July 26 at 12:50 PM
	Kamada to Host Second Quarter Financial Results Conference Call on August 2, 2016 at 8:30 am Eastern Time (NASDAQ:KMDA) finance.yahoo.com - July 26 at 12:19 PM
	Kamada Announces Appointment of Naveh Tov, M.D., Ph.D., to Vice President, Clinical Development and Medical Director for Pulmonary Diseases (NASDAQ:KMDA) finance.yahoo.com - June 23 at 7:00 AM
	FDA approves self-infusion of Glassia (NASDAQ:KMDA) seekingalpha.com - June 15 at 5:52 PM
	Kamada Ltd. :KMDA-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:KMDA) www.capitalcube.com - May 12 at 12:49 PM
	Kamada Reports 2016 First Quarter Financial Results (NASDAQ:KMDA) www.publicnow.com - May 9 at 6:56 AM
	Kamada reports 1Q loss (NASDAQ:KMDA) sg.finance.yahoo.com - May 9 at 6:34 AM
	New Kamada CEO optimistic despite European setback (NASDAQ:KMDA) www.globes.co.il - May 5 at 9:09 AM
	Kamada to Host First Quarter Financial Results Conference Call on May 9, 2016 at 8:30 am Eastern Time (NASDAQ:KMDA) finance.yahoo.com - May 4 at 8:30 AM
	Kamada Receives Two Milestone Payments under Strategic Agreements with Chiesi Farmaceutici and Baxalta (NASDAQ:KMDA) finance.yahoo.com - May 2 at 7:00 AM
	Kamada (KMDA) Commences AAT Phase 2 for Lung Transplant Rejection Prevention (NASDAQ:KMDA) www.streetinsider.com - April 7 at 1:40 PM
	Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection (NASDAQ:KMDA) www.publicnow.com - April 7 at 7:02 AM
	Kamada Submits Marketing Authorization Application with the European … (NASDAQ:KMDA) www.tmcnet.com - March 30 at 2:32 PM
	6:30 am Kamada submits a Marketing Authorization Application with the EMA for its inhaled alpha-1 antitrypsin therapy as a treatment for AAT deficiency (NASDAQ:KMDA) finance.yahoo.com - March 28 at 6:30 AM
	Kamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency (NASDAQ:KMDA) finance.yahoo.com - March 28 at 6:30 AM
	Kamada Ltd. Earnings Analysis: 2015 By the Numbers (NASDAQ:KMDA) www.capitalcube.com - February 5 at 12:35 PM
	Kamada to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference (NASDAQ:KMDA) finance.yahoo.com - February 5 at 8:56 AM
	New Strong Buy Stocks for February 4th (NASDAQ:KMDA) finance.yahoo.com - February 4 at 9:30 AM
	Kamada posts 4Q profit (NASDAQ:KMDA) sg.finance.yahoo.com - February 2 at 7:37 AM
	Kamada Reports 2015 Fourth Quarter and Full Year Financial Results (NASDAQ:KMDA) finance.yahoo.com - February 2 at 7:17 AM
	30 am Eastern time (NASDAQ:KMDA) www.wallstreet-online.de - January 27 at 10:54 AM
	Kamada to Host Fourth Quarter and Year End 2015 Financial Results Conference Call on February 2, 2016 at 8:30 am Eastern time (NASDAQ:KMDA) finance.yahoo.com - January 27 at 10:41 AM
	Kamada (KMDA) Reports Encouraging Data on Rabies Drug (NASDAQ:KMDA) finance.yahoo.com - December 29 at 4:40 PM
	Kamada Ltd. Earnings Analysis: Q3, 2015 By the Numbers (NASDAQ:KMDA) www.capitalcube.com - December 23 at 1:12 PM
	New Strong Sell Stocks for December 23rd (NASDAQ:KMDA) finance.yahoo.com - December 23 at 9:30 AM
	Kamada’s Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment (NASDAQ:KMDA) www.noodls.com - December 23 at 8:17 AM
	Kamada's rabies drug succeeds in trial (NASDAQ:KMDA) finance.yahoo.com - December 23 at 6:17 AM
	Kamada Completes Enrollment of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of AAT Deficiency (NASDAQ:KMDA) www.noodls.com - December 9 at 6:17 AM
	Kamada Provides Update on Alpha-1 Antitrypsin Development in Newly Diagnosed Type 1 Diabetes (NASDAQ:KMDA) www.noodls.com - December 9 at 6:17 AM
	KAMADA LTD Financials (NASDAQ:KMDA) finance.yahoo.com - December 8 at 1:09 PM